NAKANISHI INC.
7716・Standard Market・Precision Instruments
Dental Business
Nakanishi's core segment, accounting for approximately 59% of consolidated net sales, comprising the dental medical device business
| Period | Current | Previous | Change |
|---|---|---|---|
| Net sales (Q1 FY2026, ending December 2026) | ¥13,199 million | ¥11,323 million (Q1 FY2025, ending December 2025) | ↑ |
| Net sales YoY change | +16.6% | － | ↑ |
| Segment operating profit (Q1 FY2026, ending December 2026) | ¥4,403 million | ¥3,866 million (Q1 FY2025, ending December 2025) | ↑ |
| Segment operating profit YoY change | +13.9% | － | ↑ |
| Segment EBITDA (Q1 FY2026, ending December 2026) | ¥4,978 million | ¥4,420 million (Q1 FY2025, ending December 2025; back-calculated from +12.6% YoY) | ↑ |
| Net sales (full year FY2025, ended December 2025) | ¥48,197 million | － | ↑ |
| Segment operating profit (full year FY2025, ended December 2025) | ¥16,853 million | － | — |
Business Details
Manufactures and sells treatment handpieces, laboratory micromotors & handpieces, oral surgery handpieces, sterilizers, and other products. Operates in over 135 countries domestically and internationally, selling globally through numerous overseas subsidiaries including NSK-AMERICA CORP. and NSK EUROPE GmbH. Henry Schein, Inc. is a key customer. In Q1 FY2026 (ending December 2026), sales increased in Japan, North America, Europe, and Asia, while only the Other region saw a decline in sales.
Recent Overview
In Q1 FY2026 (ending December 2026), sales increased in Japan, North America, Europe, and Asia, achieving a 16.6% YoY increase in sales
Net sales in the Dental Business for Q1 FY2026 (ending December 2026, January-March) were ¥13,199 million (up 16.6% YoY). Sales increased in the four main regions of Japan, North America, Europe, and Asia, while the Other region saw a decline. Segment operating profit rose to ¥4,403 million (up 13.9% YoY), and segment EBITDA rose to ¥4,978 million (up 12.6% YoY). The overall consolidated sales growth rate excluding foreign exchange effects was 14.9%, suggesting that the Dental Business also benefited from genuine demand expansion.
Key Products
Growth Drivers
- Simultaneous sales increases across the four main regions of Japan, North America, Europe, and Asia (Q1 FY2026, ending December 2026 results)
- Continued sales growth in the European market (sales to Europe increased in FY2025, ended December 2025)
- Substantial increase in order intake and order backlog (order intake up 14.0% YoY, order backlog up 39.6% YoY)
- Significant increase in production volume (2,810,967 units, up 18.8% YoY)
- Securing stable earnings through expansion of OEM and DSO business (a key initiative under NV2030)
- Expansion of the product lineup, including preventive dentistry and home-visit dental care related products
Risks
- Decline in sales in the Other region (occurred in Q1 FY2026, ending December 2026)
- Dependence on sales to key customer Henry Schein, Inc. (net sales of ¥10,653 million in FY2025, ended December 2025, down 14.4% YoY)
- Foreign exchange risk (overseas sales ratio of 88.4%; fluctuations in the US dollar and euro directly affect results)
- Impact of US tariffs (pressuring gross margin along with an increase in unrealized profit)
- Uncertainty in the business environment due to geopolitical risks and trends in medical device regulations in various countries
- Intensifying price competition in emerging markets
Last updated: March 27, 2026